ReviewAnnals of surgery2013
Screening for pancreatic cancer: why, how, and who?
Review in Annals of surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 130 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients
Prospective Study of Preoperative Diagnostic Endoscopy for the Diagnosis of Occult Metastatic Lesions of Operable Pancreatic Cancer
Who cites it
130 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis.Pathology oncology research : POR · 2022Pooled it
- Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer.International journal of medical sciences · 2021Pooled it
- Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score.United European gastroenterology journal · 2019Pooled it
- The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis.Scientific reports · 2017Pooled it
- High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening.The Journal of surgical research · 2015Pooled it
- Microbiome-based diagnostic biomarkers in pancreatic ductal adenocarcinoma: Current evidence and translational challenges (Review).Oncology letters · 2026Review
- Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations.Communications medicine · 2026Review
- Unravelling the pathogenesis and therapeutic approaches of pancreatic ductal adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database.Journal of gastrointestinal cancer · 2026Article
- Systemic treatment of advanced pancreatic cancer: A Comprehensive Review.Journal of cancer & allied specialties · 2026Review
- Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers.Journal of gastroenterology and hepatology · 2026Review
- Bioinformatic Identification and Preliminary Validation of TP53, TGFB1, and NFE2L2 as Potential Ferroptosis-Related Regulators in Pancreatic Adenocarcinoma.Pharmacogenomics and personalized medicine · 2026Article
- Role of endoscopic ultrasonography or magnetic resonance imaging for screening of pancreatic cancer in low-risk individuals.World journal of clinical oncology · 2025Article
- LncRNA CASC19 promotes pancreatic cancer progression by increasing PSPC1 protein stability and facilitating the oncogenic PSPC1/ β-Catenin pathway.Molecular medicine (Cambridge, Mass.) · 2025Article
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- AI-Driven insights in pancreatic cancer imaging: from pre-diagnostic detection to prognostication.Abdominal radiology (New York) · 2025Review
- Article
- Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research.Frontiers in pharmacology · 2025Review
- Can Symptom Clusters Predict Stage, Resectability, and Survival in Pancreatic Cancer?Cancer management and research · 2025Article
- Pancreatic cancer mortality trend in Montenegro, 1990-2018.Gastroenterology report · 2025Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pancreatic cancer is the fourth most common cause of cancer mortality in the United States, with 5-year survival rates for patients with resectable tumors ranging from 15% to 20%. However, most patients presenting with distant metastases, are not resectable, and have a 5-year survival rate of close to 0%. This demonstrates a need for improved screening to identify pancreatic cancer while the tumor is still localized and amenable to surgical resection. Studies of patients with pancreatic tumors incidentally diagnosed demonstrate longer median survival than tumors discovered only when the patient is symptomatic, suggesting that early detection may improve outcome. Recent evidence from genomic sequencing indicates a 15-year interval for genetic progression of pancreatic cancer from initiation to the metastatic stage, suggesting a sufficient window for early detection. Still, many challenges remain in implementing effective screening. Early diagnosis of pancreatic cancer relies on developing screening methodologies with highly sensitive and specific biomarkers and imaging modalities. It also depends on a better understanding of the risk factors and natural history of the disease to accurately identify high-risk groups that would be best served by screening. This review summarizes our current understanding of the biology of pancreatic cancer relevant to methods available for screening. At this time, given the lack of proven benefit in this disease, screening efforts should probably be undertaken in the context of prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.